[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

YU45103A - Upotreba sarp/1 za lečenje i prevenciju skleroderme - Google Patents

Upotreba sarp/1 za lečenje i prevenciju skleroderme

Info

Publication number
YU45103A
YU45103A YU45103A YUP45103A YU45103A YU 45103 A YU45103 A YU 45103A YU 45103 A YU45103 A YU 45103A YU P45103 A YUP45103 A YU P45103A YU 45103 A YU45103 A YU 45103A
Authority
YU
Yugoslavia
Prior art keywords
sarp
scleroderma
prevention
treatment
medicament
Prior art date
Application number
YU45103A
Other languages
English (en)
Inventor
Zyberk Christine Plate
Christine Power
Jacques Colinge
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of YU45103A publication Critical patent/YU45103A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

Ovaj pronalazak se odnosi na upotrebu SARP-1 za prirpemu medikamenta lečenje i/ili prevenciju skleroderme, pre svega sistemske skleroze.[The invention relates to the use of SARP-1 (secreted apoptosis-related protein 1) for the preparation of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis.
YU45103A 2000-12-06 2001-11-30 Upotreba sarp/1 za lečenje i prevenciju skleroderme YU45103A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126771 2000-12-06
EP01118888 2001-08-17

Publications (1)

Publication Number Publication Date
YU45103A true YU45103A (sh) 2006-08-17

Family

ID=26071647

Family Applications (1)

Application Number Title Priority Date Filing Date
YU45103A YU45103A (sh) 2000-12-06 2001-11-30 Upotreba sarp/1 za lečenje i prevenciju skleroderme

Country Status (30)

Country Link
US (2) US7341995B2 (sh)
EP (2) EP1806144A3 (sh)
JP (1) JP2004525869A (sh)
KR (1) KR100804885B1 (sh)
CN (1) CN1323716C (sh)
AT (1) ATE359808T1 (sh)
AU (2) AU2002226366B2 (sh)
BG (1) BG107941A (sh)
BR (1) BR0115983A (sh)
CA (1) CA2428092A1 (sh)
CY (1) CY1107687T1 (sh)
CZ (1) CZ20031855A3 (sh)
DE (1) DE60128009T2 (sh)
DK (1) DK1411970T3 (sh)
EA (1) EA005973B1 (sh)
EE (1) EE200300213A (sh)
ES (1) ES2281463T3 (sh)
HK (1) HK1068106A1 (sh)
HR (1) HRP20030426A2 (sh)
HU (1) HUP0302738A3 (sh)
IL (1) IL156069A0 (sh)
MX (1) MXPA03005027A (sh)
NO (1) NO20032597D0 (sh)
NZ (1) NZ525774A (sh)
PL (1) PL365316A1 (sh)
PT (1) PT1411970E (sh)
SK (1) SK8472003A3 (sh)
UA (1) UA83790C2 (sh)
WO (1) WO2002046225A2 (sh)
YU (1) YU45103A (sh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE256740T1 (de) * 1997-02-06 2004-01-15 Inst Genetics Llc Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
JP4430403B2 (ja) 2002-04-10 2010-03-10 メルク セローノ ソシエテ アノニム 線維化疾患の治療および／または予防のためのオステオプロテゲリンの使用
US9046537B2 (en) * 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
PL3520815T3 (pl) 2005-02-08 2022-04-11 Genzyme Corporation Przeciwciała przeciwko TGFBETA
EP1948210A4 (en) * 2005-11-08 2010-07-14 Found Biomedical Res & Innov METHOD FOR TREATING ISCHEMIC HEART DISEASE
AU2008334608A1 (en) * 2007-12-13 2009-06-18 Merck Serono S.A. SARP-1 fusion proteins and uses thereof
EP3025715A1 (en) * 2011-03-11 2016-06-01 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2263181T5 (es) * 1996-09-24 2011-04-07 Genentech, Inc. Una familia de genes que codifican péptidos relacionados con la apoptosis, péptidos codificados por ellos y los métodos de uso de los mismos.
US5858715A (en) 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein
ATE256740T1 (de) * 1997-02-06 2004-01-15 Inst Genetics Llc Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
EA005005B1 (ru) * 1998-10-16 2004-10-28 Байоджен, Инк. ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ

Also Published As

Publication number Publication date
EP1411970B1 (en) 2007-04-18
EP1411970A2 (en) 2004-04-28
UA83790C2 (ru) 2008-08-26
NZ525774A (en) 2006-03-31
DE60128009T2 (de) 2007-08-23
AU2636602A (en) 2002-06-18
BR0115983A (pt) 2003-12-30
WO2002046225A3 (en) 2004-01-08
US20080107627A1 (en) 2008-05-08
PT1411970E (pt) 2007-05-31
EE200300213A (et) 2003-08-15
HK1068106A1 (en) 2005-04-22
HRP20030426A2 (en) 2005-04-30
DK1411970T3 (da) 2007-06-04
PL365316A1 (en) 2004-12-27
CY1107687T1 (el) 2012-05-23
ES2281463T3 (es) 2007-10-01
MXPA03005027A (es) 2003-09-05
BG107941A (bg) 2004-01-30
CA2428092A1 (en) 2002-06-13
EP1806144A3 (en) 2008-04-23
KR100804885B1 (ko) 2008-02-20
WO2002046225A2 (en) 2002-06-13
US7341995B2 (en) 2008-03-11
CN1323716C (zh) 2007-07-04
ATE359808T1 (de) 2007-05-15
US7655628B2 (en) 2010-02-02
SK8472003A3 (en) 2003-10-07
CN1553806A (zh) 2004-12-08
NO20032597L (no) 2003-06-06
EP1806144A2 (en) 2007-07-11
HUP0302738A3 (en) 2010-01-28
CZ20031855A3 (cs) 2003-09-17
AU2002226366B2 (en) 2007-03-22
EA200300639A1 (ru) 2003-12-25
DE60128009D1 (de) 2007-05-31
US20050113291A1 (en) 2005-05-26
KR20030076585A (ko) 2003-09-26
NO20032597D0 (no) 2003-06-06
IL156069A0 (en) 2003-12-23
JP2004525869A (ja) 2004-08-26
EA005973B1 (ru) 2005-08-25
HUP0302738A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
BG103646A (en) Arylsulphonamides, their analogues and application for the treatment of neurodegenerative diseases
WO1995021601A3 (en) Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
GB2365772A (en) Factor
MY136707A (en) Thrombopoietin mimetics
GB2288732B (en) Pharmaceutical compositions
AP9801392A0 (en) Concentrated antibody preparation.
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
AU2002345255A1 (en) Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
CY1107687T1 (el) Χρηση της sarp-1 για τη θεραπευτικη αντιμετωπιση και/ή προληψη της σκληροδερμιας
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
HK1001286A1 (en) Benzopyrans and their use as therapeutic agents.
WO2002062304A3 (de) Kosmetische und/oder pharmazeutische mittel acylierte aminosäure und proteinkondensat enthaltend.
WO2001085188A3 (en) Use of echinacea as a hematinic agent
EP1303520A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
BG103543A (en) The use of pramipexol in the treatment of the uneasy legs syndrome
GB9802542D0 (en) New use
MD980129A (en) Antiherpetic remedy
AP2000001945A0 (en) Leishmania cysteine proteinases.
WO2002004005A3 (en) Short peptides comprising histidine or alanine and their therapeutic use
WO2001078765A3 (de) Prophylaxe und therapie von diabetes mellitus 1 mit hilfe proteolytischer enzyme
WO2003030843A3 (de) Haarbehandlungsmittel
MD1580F1 (en) Antimutagenis agent
GB0009124D0 (en) Agent against periodontal disease